Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

As Antibiotics Recover, Centrient Maintains Focus On Sustainability

CEO Discusses Antibiotics Market, AMR, Manufacturing And European Pressures

Executive Summary

As the antibiotics market recovers in the wake of the COVID-19 pandemic, Centrient CEO Rex Clements talks to Generics Bulletin about the firm’s recent sustainability milestones as well as the cost and policy challenges faced by European manufacturing.

You may also be interested in...



Accord And Sandoz Lead Victories At GGB Awards 2022

Accord and Sandoz were the big winners at the Global Generics & Biosimilars Awards 2022 in Frankfurt, with other firms recognized including Beximco, Centrient, Dr Reddy’s, Eurofarma, Samsung Bioepis, Shanghai Henlius Biotech and Stada, as well as the US Biosimilars Forum.

EU Drug Supply In Jeopardy Without Energy Support, Warns Medicines For Europe

Medicines for Europe calls for the pharmaceutical industry to be excluded from energy restriction policies for winter 2022 in an open letter to EU governance bodies. Inflation and energy costs threaten European drug makers with closures and rationing, says the industry body.

Tambe Moves Up To Lead Biocon Biologics

Shreehas Tambe has been named as CEO of Biocon Biologics, taking over from Arun Chandavarkar, in the wake of the company’s milestone $3bn transaction for Viatris’s biosimilars business.

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB152244

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel